Matthew S. Davids, MD, MMSc, discusses data from BRUIN CLL-322 and how they may shake up the CLL treatment paradigm.
Related to this article
Advertisement
Advertisement
Trending on OncLive
1
Dr Choueiri on the Phase 3 LITESPARK-022 Trial of Belzutifan Plus Pembrolizumab in ccRCC
2
Bexobrutideg Aims to Overcome Resistance Mutations in R/R CLL
3
Adjuvant Immunotherapy, Risk Stratification, and Multidisciplinary Care Redefine CSCC Management
4
BPM31510 Plus Chemoradiation Drives Encouraging OS Trend in Newly Diagnosed Glioblastoma
5